GPhA Offers Risk-Based Approach To “Follow-On” Biologics Immunogenicity
Executive Summary
Pre-approval testing for "follow-on" biologics should focus on determining product factors with the greatest risk of immunogenicity, the Generic Pharmaceutical Association said
You may also be interested in...
EU Biosimilar Guidance Offers Window To Bypass Comparative Trials
Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8
EU Biosimilar Guidance Offers Window To Bypass Comparative Trials
Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8
FDA Generic Biologics Short-Term Plan Includes Immunogenicity Document
Immunogenicity and chemistry of follow-on biologics will be among the first issues FDA tackles in documents issued on the topic, Acting Commissioner Lester Crawford said at the Generic Pharmaceutical Association's annual meeting in Boca Raton, Fla